Literature DB >> 20649579

Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors.

M S García-Gutiérrez1, J M Pérez-Ortiz, A Gutiérrez-Adán, J Manzanares.   

Abstract

BACKGROUND AND
PURPOSE: The present study evaluated the role of CB(2) receptors in the regulation of depressive-like behaviours. Transgenic mice overexpressing the CB(2) receptor (CB2xP) were challenged with different types of acute and chronic experimental paradigms to evaluate their response in terms of depressive-like behaviours. EXPERIMENTAL APPROACH: Tail suspension test (TST), novelty-suppressed feeding test (NSFT) and unpredictable chronic mild stress tests (CMS) were carried out in CB2xP mice. Furthermore, acute and chronic antidepressant-like effects of the CB(2) receptor-antagonist AM630 were evaluated by means of the forced swimming test (FST) and CMS, respectively, in wild-type (WT) and CB2xP mice. CB(2) gene expression, brain-derived neurotrophic factor (BDNF) gene and protein expressions were studied in mice exposed to CMS by real-time PCR and immunohistochemistry, respectively. KEY
RESULTS: Overexpression of CB(2) receptors resulted in decreased depressive-like behaviours in the TST and NSFT. CMS failed to alter the TST and sucrose consumption in CB2xP mice. In addition, no changes in BDNF gene and protein expression were observed in stressed CB2xP mice. Interestingly, acute administration of AM630 (1 and 3 mg x kg(-1), i.p.) exerted antidepressant-like effects on the FST in WT, but not in CB2xP mice. Chronic administration of AM630 for 4 weeks (1 mg x kg(-1); twice daily, i.p.) blocked the effects of CMS on TST, sucrose intake, CB(2) receptor gene, BDNF gene and protein expression in WT mice. CONCLUSION AND IMPLICATIONS: Taken together, these results suggest that increased CB(2) receptor expression significantly reduced depressive-related behaviours and that the CB(2) receptor could be a new potential therapeutic target for depressive-related disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649579      PMCID: PMC2936848          DOI: 10.1111/j.1476-5381.2010.00819.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

1.  Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper.

Authors:  Janne Grønli; Clive Bramham; Robert Murison; Tambudzai Kanhema; Eldbjørg Fiske; Bjørn Bjorvatn; Reidun Ursin; Chiara M Portas
Journal:  Pharmacol Biochem Behav       Date:  2007-01-03       Impact factor: 3.533

2.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

3.  Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain.

Authors:  Emmanuel S Onaivi
Journal:  Neuropsychobiology       Date:  2007-03-15       Impact factor: 2.328

4.  Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms.

Authors:  Song Li; Che Wang; Minwei Wang; Wei Li; Kinzo Matsumoto; Yiyuan Tang
Journal:  Life Sci       Date:  2007-01-12       Impact factor: 5.037

5.  The effects of chronic antidepressant treatment in an animal model of anxiety.

Authors:  S R Bodnoff; B Suranyi-Cadotte; D H Aitken; R Quirion; M J Meaney
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 6.  CB2 receptors in the brain: role in central immune function.

Authors:  G A Cabral; E S Raborn; L Griffin; J Dennis; F Marciano-Cabral
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

7.  Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice.

Authors:  Michel A Steiner; Giovanni Marsicano; Eric J Nestler; Florian Holsboer; Beat Lutz; Carsten T Wotjak
Journal:  Psychoneuroendocrinology       Date:  2007-10-31       Impact factor: 4.905

Review 8.  Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists.

Authors:  C A Lunn; E-P Reich; J S Fine; B Lavey; J A Kozlowski; R W Hipkin; D J Lundell; L Bober
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

9.  Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects.

Authors:  Emmanuel S Onaivi; Hiroki Ishiguro; Jian-Ping Gong; Sejal Patel; Paul A Meozzi; Lester Myers; Alex Perchuk; Zoila Mora; Patricia A Tagliaferro; Eileen Gardner; Alicia Brusco; B Emmanuel Akinshola; Bruce Hope; Javier Lujilde; Toshiya Inada; Shinya Iwasaki; David Macharia; Lindsey Teasenfitz; Tadao Arinami; George R Uhl
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

10.  COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.

Authors:  Yiangos Yiangou; Paul Facer; Pascal Durrenberger; Iain P Chessell; Alan Naylor; Chas Bountra; Richard R Banati; Praveen Anand
Journal:  BMC Neurol       Date:  2006-03-02       Impact factor: 2.474

View more
  67 in total

1.  Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice.

Authors:  Hai-Ying Zhang; Ming Gao; Qing-Rong Liu; Guo-Hua Bi; Xia Li; Hong-Ju Yang; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Genetic Versus Pharmacological Assessment of the Role of Cannabinoid Type 2 Receptors in Alcohol Reward-Related Behaviors.

Authors:  Matthew S Powers; Kristen R Breit; Julia A Chester
Journal:  Alcohol Clin Exp Res       Date:  2015-12       Impact factor: 3.455

Review 3.  The molecular and cellular mechanisms of depression: a focus on reward circuitry.

Authors:  Megan E Fox; Mary Kay Lobo
Journal:  Mol Psychiatry       Date:  2019-04-09       Impact factor: 15.992

4.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

Review 5.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

6.  Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors.

Authors:  María S García-Gutiérrez; Borja García-Bueno; Silvia Zoppi; Juan C Leza; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 7.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

8.  Cannabinoid 2 receptor- and beta Arrestin 2-dependent upregulation of serotonin 2A receptors.

Authors:  J M Franklin; T Vasiljevik; T E Prisinzano; G A Carrasco
Journal:  Eur Neuropsychopharmacol       Date:  2012-07-28       Impact factor: 4.600

9.  Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice.

Authors:  S Zoppi; J L Madrigal; J R Caso; M S García-Gutiérrez; J Manzanares; J C Leza; B García-Bueno
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

10.  Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.

Authors:  Jade M Franklin; Gonzalo A Carrasco
Journal:  Synapse       Date:  2012-12-08       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.